Johnson & Johnson's Options: A Look at What the Big Money Is Thinking
Companies Heavily Investing in AI Have Low Quant Valuation Grades
Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries
J&J Prostate Cancer Therapy Outperforms in Real-world Study
Gilead Signs Deals With Six Drugmakers for Generic Lenacapavir
Johnson & Johnson Presents Results From Study Showing That ERLEADA Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival Compared To Enzalutamide In Patients With Metastatic Castration-sensitive Prostate Cancer
loading...